Log in

AxoGen Stock Forecast, Price & News

+0.11 (+0.77 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $14.38
50-Day Range
MA: $13.75
52-Week Range
Now: $14.38
Volume68,354 shs
Average Volume408,522 shs
Market Capitalization$577.01 million
P/E RatioN/A
Dividend YieldN/A
AxoGen, Inc., together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More
AxoGen logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:AXGN



Sales & Book Value

Annual Sales$106.71 million
Book Value$3.03 per share


Net Income$-29,140,000.00


Market Cap$577.01 million
Next Earnings Date2/22/2021 (Estimated)
+0.11 (+0.77 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

AxoGen (NASDAQ:AXGN) Frequently Asked Questions

How has AxoGen's stock price been impacted by Coronavirus?

AxoGen's stock was trading at $10.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AXGN stock has increased by 34.4% and is now trading at $14.38.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of AxoGen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AxoGen
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than AxoGen?

Wall Street analysts have given AxoGen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AxoGen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AxoGen's next earnings date?

AxoGen is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for AxoGen

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) issued its earnings results on Tuesday, November, 3rd. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.18. AxoGen had a negative return on equity of 19.83% and a negative net margin of 22.98%.
View AxoGen's earnings history

What guidance has AxoGen issued on next quarter's earnings?

AxoGen issued an update on its third quarter 2020 After-Hours earnings guidance on Tuesday, September, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $30 million, compared to the consensus revenue estimate of $23.04 million.

What price target have analysts set for AXGN?

5 brokers have issued twelve-month price targets for AxoGen's shares. Their forecasts range from $13.00 to $24.00. On average, they anticipate AxoGen's stock price to reach $17.90 in the next twelve months. This suggests a possible upside of 24.5% from the stock's current price.
View analysts' price targets for AxoGen

Are investors shorting AxoGen?

AxoGen saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 1,120,000 shares, an increase of 15.6% from the October 15th total of 969,100 shares. Based on an average trading volume of 277,300 shares, the days-to-cover ratio is currently 4.0 days. Currently, 3.1% of the company's stock are sold short.
View AxoGen's Short Interest

Who are some of AxoGen's key competitors?

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

Who are AxoGen's key executives?

AxoGen's management team includes the following people:
  • Ms. Karen Zaderej, Chairman, Pres & CEO (Age 58, Pay $999.96k)
  • Mr. Peter J. Mariani, Chief Financial Officer (Age 56, Pay $548.03k)
  • Ms. Maria D. Martinez, Chief HR Officer (Age 52, Pay $460.48k)
  • Mr. Eric A. Sandberg, Chief Commercial Officer (Age 55, Pay $476.8k)
  • Mr. Angelo G. Scopelianos Ph.D., VP of R&D (Age 65, Pay $554.14k)
  • Mr. Michael Donovan, VP of Operations (Age 55)
  • Mr. Brad Ottinger, Gen. Counsel & Chief Compliance Officer
  • Mr. Gregory Davault, VP of Marketing (Age 52)
  • Ms. Isabelle Billet, Chief Strategy & Bus. Devel. Officer (Age 58)
  • Mr. David Hansen, VP of Fin. & Treasurer (Age 59)

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by many different institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (16.42%), BlackRock Inc. (7.14%), First Light Asset Management LLC (4.31%), William Blair Investment Management LLC (3.16%), State Street Corp (2.52%) and Great West Life Assurance Co. Can (1.60%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Michael Patrick Donovan, Peter J Mariani and Quentin S Blackford.
View institutional ownership trends for AxoGen

Which institutional investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., State Street Corp, ArrowMark Colorado Holdings LLC, Assenagon Asset Management S.A., Wells Fargo & Company MN, ExodusPoint Capital Management LP, Aigen Investment Management LP, and Paradigm Capital Management Inc. NY. Company insiders that have sold AxoGen company stock in the last year include Karen L Zaderej, Michael Patrick Donovan, and Peter J Mariani.
View insider buying and selling activity for AxoGen

Which institutional investors are buying AxoGen stock?

AXGN stock was acquired by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Great West Life Assurance Co. Can, Perkins Capital Management Inc., William Blair Investment Management LLC, Granite Point Capital Management L.P., Genesee Capital Advisors LLC, Skandinaviska Enskilda Banken AB publ , and Trexquant Investment LP. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej, and Quentin S Blackford.
View insider buying and selling activity for AxoGen

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $14.38.

How big of a company is AxoGen?

AxoGen has a market capitalization of $577.01 million and generates $106.71 million in revenue each year. The medical equipment provider earns $-29,140,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. AxoGen employs 371 workers across the globe.

What is AxoGen's official website?

The official website for AxoGen is www.axogeninc.com.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.